Additional file 11 of Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Elgamal, Ola; Mehmood, Abeera; Jeon, Jae; Carmichael, Bridget; Lehman, Amy; Orwick, Shelley; Truxall, Jean; Goettl, Virginia; Wasmuth, Ronni; Tran, Minh; Mitchell, Shaneice; Lapalombella, Rosa; Eathiraj, Sudharshan; Schwartz, Brian; Stegmaier, Kimberly; Baker, Sharyn; Hertlein, Erin; Byrd, John

doi:10.6084/m9.figshare.11759508.v1

13045_2019_821_MOESM11_ESM.pdf (109.87 kB)

Additional file 11 of Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

journal contribution

posted on 2020-01-29, 04:39 authored by Ola Elgamal, Abeera Mehmood, Jae Jeon, Bridget Carmichael, Amy Lehman, Shelley Orwick, Jean Truxall, Virginia Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn Baker, Erin Hertlein, John Byrd

Additional file 11. Supplementary Information 1.

Funding

National Cancer Institute

History

Usage metrics

Keywords

Acute myeloid leukemia Multi-kinase inhibitor ArQule 531

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 11 of Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Funding

National Cancer Institute

History

Usage metrics

Categories

Keywords

Licence

Exports